Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-class new generation drugs for renal anemia. This extensive meta-analysis of randomized controlled trials (RCTs) was designed to provide clear information on the efficacy and safety of HIF-PHIs on anemia in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bin, Yin, Qing, Han, Yu-Chen, Wu, Min, Li, Zuo-Lin, Tu, Yan, Zhou, Le-ting, Wei, Qing, Liu, Hong, Tang, Ri-Ning, Cao, Jing-Yuan, Lv, Lin-Li, Liu, Bi-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946011/
https://www.ncbi.nlm.nih.gov/pubmed/32869703
http://dx.doi.org/10.1080/0886022X.2020.1811121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946011/
https://www.ncbi.nlm.nih.gov/pubmed/32869703
http://dx.doi.org/10.1080/0886022X.2020.1811121

Ejemplares similares